$ACOG
Alpha Cognition Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024067658 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.413M $1.231M
YoY Change -0.97% 33.95%
% of Gross Profit
Research & Development $996.0K $967.2K $1.151M
YoY Change -32.21% -23.46% -52.74%
% of Gross Profit
Depreciation & Amortization $236.00 $237.00 $21.12K
YoY Change -98.88% -98.88% -8.21%
% of Gross Profit
Operating Expenses $2.488M $2.421M $2.403M
YoY Change -10.73% -10.7% -28.85%
Operating Profit -$2.488M -$2.421M
YoY Change -10.06% -11.25%
Interest Expense $146.0K -$3.494M
YoY Change -213.06% 372.71%
% of Operating Profit
Other Income/Expense, Net $627.9K $305.7K $227.8K
YoY Change 1816.6% -441.5%
Pretax Income -$2.116M -$5.797M
YoY Change -24.2% 40.63%
Income Tax
% Of Pretax Income
Net Earnings -$1.860M -$2.116M -$5.797M
YoY Change -44.03% -24.2% 40.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31 -$0.01
Diluted Earnings Per Share -$0.31 -$0.01 -$0.05
COMMON SHARES
Basic Shares Outstanding 150.9M shares 150.2M shares
Diluted Shares Outstanding 6.030M shares 150.2M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.019M $1.404M
YoY Change -16.33% -32.61%
Cash & Equivalents $3.666M $1.019M $1.404M
Short-Term Investments
Other Short-Term Assets $495.1K $456.7K
YoY Change 306.04% 83.39%
Inventory
Prepaid Expenses $710.3K $253.8K $206.4K
Receivables
Other Receivables
Total Short-Term Assets $4.514M $1.514M $1.918M
YoY Change 294.43% 13.01% -17.76%
LONG-TERM ASSETS
Property, Plant & Equipment $1.011K $1.247K $1.720K
YoY Change -55.07% -54.98% -54.97%
Goodwill
YoY Change
Intangibles $432.7K $452.5K $532.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $80.00K $114.3K
YoY Change
Total Long-Term Assets $513.7K $568.0K $533.7K
YoY Change -7.41% -1.38% -13.67%
TOTAL ASSETS
Total Short-Term Assets $4.514M $1.514M $1.918M
Total Long-Term Assets $513.7K $568.0K $533.7K
Total Assets $5.028M $2.082M $2.452M
YoY Change 195.88% 8.68% -16.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $790.3K $484.2K $475.6K
YoY Change 12.39% 3.11% -76.41%
Accrued Expenses $758.0K $918.6K
YoY Change 39.53% 10.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.220M
YoY Change 0.74%
Long-Term Debt Due $300.0K
YoY Change
Total Short-Term Liabilities $3.006M $1.571M $2.625M
YoY Change 3.78% 55.12% -35.3%
LONG-TERM LIABILITIES
Long-Term Debt $911.5K $0.00
YoY Change -20.07%
Other Long-Term Liabilities $74.25K $46.77K $4.540M
YoY Change -98.5% -79.94% 2018.66%
Total Long-Term Liabilities $74.25K $46.77K $4.540M
YoY Change -98.5% -96.59% 2018.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.006M $1.571M $2.625M
Total Long-Term Liabilities $74.25K $46.77K $4.540M
Total Liabilities $7.948M $3.475M $7.165M
YoY Change 1.4% 45.65% 67.75%
SHAREHOLDERS EQUITY
Retained Earnings -$70.63M -$68.77M -$61.65M
YoY Change
Common Stock $49.15M $49.01M $39.76M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.920M -$1.393M -$4.713M
YoY Change
Total Liabilities & Shareholders Equity $5.028M $2.082M $2.452M
YoY Change 195.88% 8.68% -16.9%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q4
OPERATING ACTIVITIES
Net Income -$1.860M -$2.116M -$5.797M
YoY Change -44.03% -24.2% 40.63%
Depreciation, Depletion And Amortization $236.00 $237.00 $21.12K
YoY Change -98.88% -98.88% -8.21%
Cash From Operating Activities -$1.419M -$2.008M
YoY Change -47.07% -19.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.389M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 2.594M
YoY Change -3205.39% -129817.0%
NET CHANGE
Cash From Operating Activities -1.419M -2.008M
Cash From Investing Activities 0.000
Cash From Financing Activities 190.0K 2.594M
Net Change In Cash -1.229M 586.2K
YoY Change -54.26% -123.35%
FREE CASH FLOW
Cash From Operating Activities -$1.419M -$2.008M
Capital Expenditures $0.00
Free Cash Flow -$2.008M
YoY Change -19.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-278997
dei Entity Registrant Name
EntityRegistrantName
Alpha Cognition Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
1200 - 750 West Pender Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V6C
dei City Area Code
CityAreaCode
(604)
dei Local Phone Number
LocalPhoneNumber
564-9244
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
150855536 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1018862 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1404160 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
175321 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90413 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
319796 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
366316 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1513979 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1918439 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114286 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1247 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1721 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
452490 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
532010 usd
CY2024Q2 us-gaap Assets
Assets
2082002 usd
CY2023Q4 us-gaap Assets
Assets
2452170 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1242237 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1394117 usd
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
28898 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
10413 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1571135 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2615993 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
946105 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4455747 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46765 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84125 usd
CY2024Q2 us-gaap Liabilities
Liabilities
3475468 usd
CY2023Q4 us-gaap Liabilities
Liabilities
7155865 usd
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150505536 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150505536 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
118208989 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
118208989 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
49009464 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
39760287 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
62 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
62 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18467705 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17288430 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104301 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104301 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68766396 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61648173 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1393466 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4703695 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2082002 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2452170 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
967200 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1246226 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1883916 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2344164 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1454011 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1481832 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4948813 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2370241 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2421211 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2728058 usd
us-gaap Operating Expenses
OperatingExpenses
6832729 usd
us-gaap Operating Expenses
OperatingExpenses
4714405 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2421211 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2728058 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6832729 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4714405 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6862 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-18302 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-21491 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9717 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2160 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2175 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
14230 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2347 usd
CY2024Q2 us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
138561 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
272340 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
15216 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1533 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
23474 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4408 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-187056 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
71856 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
432933 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
16658 usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
55000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
305699 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-89516 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-285494 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9002 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2115512 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2817574 usd
us-gaap Net Income Loss
NetIncomeLoss
-7118223 usd
us-gaap Net Income Loss
NetIncomeLoss
-4723407 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
27898 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8341 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2115512 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2789676 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7118223 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4731748 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150234327 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94604510 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146925149 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86273053 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
184919 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1800 usd
CY2024Q2 acog Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
160000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
375327 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2115512 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1393466 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1274183 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10500 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
963293 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
27898 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2817574 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-541700 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4703695 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3732469 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2273949 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-405753 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1800 usd
acog Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
160000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
723412 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3942575 usd
us-gaap Net Income Loss
NetIncomeLoss
-7118223 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1393466 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1320177 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4506055 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-208686 usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
10500 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1202356 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-8341 usd
us-gaap Net Income Loss
NetIncomeLoss
-4723407 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-541700 usd
us-gaap Net Income Loss
NetIncomeLoss
-7118223 usd
us-gaap Net Income Loss
NetIncomeLoss
-4723407 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
40828 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
42240 usd
us-gaap Government Assistance Operating Expense
GovernmentAssistanceOperatingExpense
66423 usd
acog Reversal Of Accrued Interest Income Related Party
ReversalOfAccruedInterestIncomeRelatedParty
-2550 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
432933 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
16658 usd
acog Change In Fair Value Of Bonus Rights Liability
ChangeInFairValueOfBonusRightsLiability
-37360 usd
acog Change In Fair Value Of Bonus Rights Liability
ChangeInFairValueOfBonusRightsLiability
2123 usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
55000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
39166 usd
us-gaap Share Based Compensation
ShareBasedCompensation
723412 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1202356 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2273949 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
67766 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-127109 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-151880 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1832532 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3873814 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5165453 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3732469 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4506055 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1800 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10500 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
160000 usd
acog Proceeds Received From Restricted Government Grant
ProceedsReceivedFromRestrictedGovernmentGrant
290825 usd
acog Amounts Paid From Restricted Government Grant Funds
AmountsPaidFromRestrictedGovernmentGrantFunds
205917 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
405753 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
208686 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3573424 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4307869 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-8341 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-300390 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
300000 usd
CY2024Q2 acog Debt Instrument Due Date
DebtInstrumentDueDate
2024-12-31
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
1:1
us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
180000 shares
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-865925 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1494573 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2083696 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1194183 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1217771 usd
CY2024Q2 us-gaap Deposit Assets
DepositAssets
1018862 usd
CY2023Q2 us-gaap Deposit Assets
DepositAssets
1217771 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
175321 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1194183 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1217771 usd
us-gaap Interest Paid Net
InterestPaidNet
37754 usd
us-gaap Interest Paid Net
InterestPaidNet
26187 usd
acog Reallocation Of Fair Value Of Share Options Upon Exercise
ReallocationOfFairValueOfShareOptionsUponExercise
126382 usd
acog Reallocation Of Fair Value Of Share Options Upon Exercise
ReallocationOfFairValueOfShareOptionsUponExercise
676632 usd
acog Reclassification Of Derivative Liability For Warrants Repriced From Cad To Usd Exercise Price
ReclassificationOfDerivativeLiabilityForWarrantsRepricedFromCADToUSDExercisePrice
3942575 usd
us-gaap Stock Issued1
StockIssued1
928874 usd
us-gaap Stock Issued1
StockIssued1
618004 usd
acog Warrants Issued For Share Issuance Costs
WarrantsIssuedForShareIssuanceCosts
582245 usd
acog Warrants Issued For Share Issuance Costs
WarrantsIssuedForShareIssuanceCosts
73018 usd
acog Common Shares Issued For Services
CommonSharesIssuedForServices
2273949000000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha Cognition Inc. (“ACI” or the “Company”) is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment with Traumatic Brain Injury (“TBI”), for which there are limited or no treatment options. The registered and records office of the Company is 1200 – 750 West Pender Street, Vancouver, BC, V6C 2T8. As of May 1, 2023, the Company’s common shares commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “ACOG”, previously the Company’s shares were traded on the TSX Venture Exchange (“TSX-V”) until April 28, 2023, when the Company had them delisted. The Company’s shares also trade on the Over-The-Counter Markets (“OTC”) under the trading symbol “ACOGF”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt">On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (FDA) for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b><i>Going Concern </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed interim consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company has not generated revenues from its operations to date and as of June 30, 2024, had working capital deficit of $57,156 and an accumulated deficit of $68,766,396 which has been primarily financed by equity. The Company’s continuing operations, as intended, are dependent upon its ability to generate cash flows or obtain additional financing. Management is of the opinion that it does not have sufficient working capital to meet the Company’s liabilities and commitments as they become due for the 12 months from the date these financial statements. Management intends to finance operating costs over the next twelve months with private placements and public offerings of the Company’s common shares and funds received from the exercise of warrants and options. Additionally, the Company will also consider funding that may arise through partnerships activities and debt. There is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt">These </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unaudited condensed interim <span style="letter-spacing: -0.1pt">consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption was not appropriate for these</span> unaudited condensed interim <span style="letter-spacing: -0.1pt">consolidated financial statements, adjustments would be necessary to the balance sheet used. Such adjustments could be material</span>.</span></p>
CY2024Q2 acog Working Capital
WorkingCapital
57156 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68766396 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates and Assumptions</i> – </b>The preparation of these unaudited condensed interim consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the unaudited condensed interim consolidated financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, to ensure that those estimates effectively reflect changes in the Company’s business and new information as it becomes available. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results could differ materially from these estimates under different assumptions or conditions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk </i></b><i>– </i>The Company’s financial instruments subject to concentrations of credit risk consists primarily of cash and cash equivalents. Cash is deposited with financial institutions with high credit quality which are typically in excess of insured limits. Additionally, as of June 30, 2024, the Company had $430,562 (December 31, 2023 - $475,567) in cash held at its payment processing company in a demand account to be used to pay accounts payable. During the six months ending June 30, 2024, and 2023, the Company did not experience any loss related to these concentrations.</span></p>
CY2024Q2 us-gaap Cash
Cash
430562 usd
CY2023Q4 us-gaap Cash
Cash
475567 usd
acog Schedule Of Estimated Useful Lives Of Equipment
ScheduleOfEstimatedUsefulLivesOfEquipment
Depreciation is charged over the estimated useful lives using the declining balance method as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other equipment </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table>
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.50 pure
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
5251 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
7800 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46765 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84125 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
946105 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4455747 usd
CY2024Q2 us-gaap Fair Value Concentration Of Risk Foreign Currency Contracts
FairValueConcentrationOfRiskForeignCurrencyContracts
57000 cad
CY2023Q4 us-gaap Fair Value Concentration Of Risk Foreign Currency Contracts
FairValueConcentrationOfRiskForeignCurrencyContracts
36000 cad
acog Change In Exchange Rate
ChangeInExchangeRate
0.10 pure
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
4200 usd
acog Grant Income
GrantIncome
272340 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
175321 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90413 usd
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
28898 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
10413 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
272340 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
272340 usd
CY2023Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
150000 usd
CY2024Q2 us-gaap Advances To Affiliate
AdvancesToAffiliate
55000 usd
CY2023Q4 us-gaap Advances To Affiliate
AdvancesToAffiliate
55000 usd
CY2024Q2 us-gaap Principal Amount Outstanding On Loans Securitized
PrincipalAmountOutstandingOnLoansSecuritized
55000 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
4195 usd
CY2024Q2 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
49121 usd
CY2023Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
100036 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
253758 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
206377 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
16917 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
59903 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
319796 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
366316 usd
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
114286 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12370 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12370 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11123 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10649 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1247 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1721 usd
CY2024Q2 us-gaap Depreciation
Depreciation
237 usd
CY2023Q2 us-gaap Depreciation
Depreciation
526 usd
us-gaap Depreciation
Depreciation
474 usd
us-gaap Depreciation
Depreciation
1052 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
484206 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
475553 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
275574 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
127284 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
482457 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
791280 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1242237 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1394117 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1185633 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
733143000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
452490000 usd
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P5Y8M1D
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1235633 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
703623000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
532010000 usd
CY2023 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P6Y7M9D
CY2024Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
19760 usd
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
20594 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
40354 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
-41188 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
39522 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
79042 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
79042 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
79042 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
79042 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
96800 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
452490 usd
CY2015Q1 us-gaap Notes Payable
NotesPayable
1400000 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
1211463 usd
us-gaap Accretion Expense
AccretionExpense
37754 usd
us-gaap Accretion Expense
AccretionExpense
26187 usd
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1800 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
89631 usd
CY2023 us-gaap Payments For Commissions
PaymentsForCommissions
172480 usd
CY2023 us-gaap Legal Fees
LegalFees
15428 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1 shares
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
27000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1344480 usd
CY2023Q2 acog Aggregate Proceeds Percentage
AggregateProceedsPercentage
0.10 pure
CY2023Q2 us-gaap Product Warranty Liquidation Proceeds Percentage
ProductWarrantyLiquidationProceedsPercentage
0.10 pure
CY2023Q2 acog Gross Proceeds Percentage
GrossProceedsPercentage
0.05 pure
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-10-16
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-11-08
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.31
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-12-22
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86101 shares
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
80039 usd
CY2023Q3 acog Reclassification Of Charged To Equity
ReclassificationOfChargedToEquity
4541545 usd
CY2023Q3 us-gaap Investment Company Increase Decrease From Share Transaction
InvestmentCompanyIncreaseDecreaseFromShareTransaction
4541545 usd
CY2023 acog Repriced Of Warrants
RepricedOfWarrants
11777336 shares
acog Reclassification Of Derivative Liability Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityPerChangeInFunctionalCurrency
3942575 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
432933 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.20 pure
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
581391 usd
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
165000 shares
CY2018Q3 us-gaap Payment For Management Fee
PaymentForManagementFee
13333 usd
CY2022Q3 us-gaap Fee Income
FeeIncome
7500 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
440425 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
672550 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
1211463 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1816655 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1952605 usd
CY2015Q1 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
15000000 eur
CY2015Q1 acog Net Sales Revenue Percentage
NetSalesRevenuePercentage
0.03 pure
CY2015Q1 acog Sublicensing Revenue
SublicensingRevenue
0.10 pure
CY2015Q1 acog Milestone Payment
MilestonePayment
0.25 pure
CY2015Q1 acog Royalty Payment Percentage
RoyaltyPaymentPercentage
0.01 pure
CY2015Q1 us-gaap Revenues
Revenues
100000000 usd
CY2015Q1 us-gaap Notes Payable
NotesPayable
1400000 usd
CY2016Q1 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
2142920 usd
CY2016Q1 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
2000000 eur
CY2016Q1 acog Net Sales Revenue Percentage
NetSalesRevenuePercentage
0.01 pure
CY2016Q1 acog Sublicensing Revenue
SublicensingRevenue
0.02 pure
CY2016Q1 acog Milestone Payment
MilestonePayment
0.02 pure
CY2020Q4 us-gaap Payments For Purchase Of Other Assets1
PaymentsForPurchaseOfOtherAssets1
50000 usd
CY2020Q4 acog Royalty Percentage
RoyaltyPercentage
0.015 pure
CY2020Q4 acog Commercial Sales
CommercialSales
2000000 usd
CY2020Q4 acog Milestone Payment
MilestonePayment
0.10 pure
CY2020Q4 acog Received Of Upfrontpayments
ReceivedOfUpfrontpayments
2000000 usd
CY2020Q4 acog License Agreement Terms
LicenseAgreementTerms
P11Y
CY2020Q4 us-gaap Other Notes Payable
OtherNotesPayable
2000000 usd
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
50000 usd
CY2023Q2 us-gaap Payments For Fees
PaymentsForFees
480000 usd
CY2023Q4 us-gaap Payments For Fees
PaymentsForFees
160000 usd
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
320000 usd
CY2024Q2 us-gaap Financial Instruments Owned Other At Fair Value
FinancialInstrumentsOwnedOtherAtFairValue
453737 usd
CY2023Q4 us-gaap Financial Instruments Owned Other At Fair Value
FinancialInstrumentsOwnedOtherAtFairValue
533731 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2115512 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2817574 usd
us-gaap Net Income Loss
NetIncomeLoss
-7118223 usd
us-gaap Net Income Loss
NetIncomeLoss
-4723407 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150234327 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94604510 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146925149 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86273053 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
88373310 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
66993328 shares
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
350000 shares
acog Class Of Warrant Right Exercise
ClassOfWarrantRightExercise
350000 shares
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 acog Non Rule10b51 Arrangement Modified Flag
NonRule10b51ArrangementModifiedFlag
false
CY2024Q2 acog Rule10b51 Arrangement Modified Flag
Rule10b51ArrangementModifiedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q2 us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
usd
CY2024Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2023Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2024Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
CY2023Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146925149 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150234327 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86273053 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94604510 shares
us-gaap Government Assistance Operating Expense
GovernmentAssistanceOperatingExpense
usd
acog Reversal Of Accrued Interest Income Related Party
ReversalOfAccruedInterestIncomeRelatedParty
usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
acog Proceeds Received From Restricted Government Grant
ProceedsReceivedFromRestrictedGovernmentGrant
usd
acog Amounts Paid From Restricted Government Grant Funds
AmountsPaidFromRestrictedGovernmentGrantFunds
usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
acog Reclassification Of Derivative Liability For Warrants Repriced From Cad To Usd Exercise Price
ReclassificationOfDerivativeLiabilityForWarrantsRepricedFromCADToUSDExercisePrice
usd
acog Common Shares Issued For Services
CommonSharesIssuedForServices
usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
acog Grant Income
GrantIncome
usd
acog Grant Income
GrantIncome
usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146925149 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150234327 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86273053 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94604510 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001655923
dei No Trading Symbol Flag
NoTradingSymbolFlag
true

Files In Submission

Name View Source Status
0001213900-24-067658-index-headers.html Edgar Link pending
0001213900-24-067658-index.html Edgar Link pending
0001213900-24-067658.txt Edgar Link pending
0001213900-24-067658-xbrl.zip Edgar Link pending
acog-20240630.xsd Edgar Link pending
ea0210457-10q_alpha.htm Edgar Link pending
ea021045701ex31-1_alpha.htm Edgar Link pending
ea021045701ex31-2_alpha.htm Edgar Link pending
ea021045701ex32-1_alpha.htm Edgar Link pending
ea021045701ex32-2_alpha.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
acog-20240630_lab.xml Edgar Link unprocessable
acog-20240630_pre.xml Edgar Link unprocessable
acog-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0210457-10q_alpha_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acog-20240630_def.xml Edgar Link unprocessable